Albertini MR - Search Results

1

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Shusterman S, et al. Among authors: albertini mr. J Clin Oncol. 2010 Nov 20;28(33):4969-75. doi: 10.1200/JCO.2009.27.8861. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921469 Free PMC article. Clinical Trial.

2

Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2.

Albertini MR, Hank JA, Sondel PM. Albertini MR, et al. Biotherapy. 1992;4(3):189-98. doi: 10.1007/BF02174205. Biotherapy. 1992. PMID: 1599802 Review. No abstract available.

3

Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells.

Albertini MR, Gibson DF, Robinson SP, Howard SP, Tans KJ, Lindstrom MJ, Robinson RR, Tormey DC, Jordan VC, Sondel PM. Albertini MR, et al. J Immunother (1991). 1992 Jan;11(1):30-9. doi: 10.1097/00002371-199201000-00004. J Immunother (1991). 1992. PMID: 1734946

4

The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.

Albertini MR, Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Bechhofer R, Storer B, Sondel PM. Albertini MR, et al. Cancer. 1990 Dec 15;66(12):2457-64. doi: 10.1002/1097-0142(19901215)66:12<2457::aid-cncr2820661203>3.0.co;2-l. Cancer. 1990. PMID: 2249185 Clinical Trial.

5

Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.

Albertini MR, Oettel KR, Weil-Hillman G, Lindstrom MJ, Schell K, Hank JA, Sondel PM. Albertini MR, et al. J Biol Response Mod. 1990 Oct;9(5):456-62. J Biol Response Mod. 1990. PMID: 2254758

6

Activation of multiple effector mechanisms to enhance tumor immunotherapy.

Hank JA, Albertini MR, Schiller J, Sondel PM. Hank JA, et al. Among authors: albertini mr. J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):329-35. doi: 10.1097/00002371-199311000-00013. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8280716 Review.

7

A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.

Gambacorti-Passerini C, Hank JA, Albertini MR, Borchert AA, Moore KH, Schiller JH, Bechhofer R, Borden EC, Storer B, Sondel PM. Gambacorti-Passerini C, et al. Among authors: albertini mr. J Immunother Emphasis Tumor Immunol. 1993 Jan;13(1):43-8. doi: 10.1097/00002371-199301000-00006. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8435431 Clinical Trial.

8

A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.

Schiller JH, Hank J, Storer B, Borchert AA, Moore KH, Albertini M, Bechhofer R, Wesley O, Brown RR, Bastin AM, et al. Schiller JH, et al. Cancer Res. 1993 Mar 15;53(6):1286-92. Cancer Res. 1993. PMID: 8443808 Clinical Trial.

9

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.

Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM. Surfus JE, et al. Among authors: albertini mr. J Immunother Emphasis Tumor Immunol. 1996 May;19(3):184-91. doi: 10.1097/00002371-199605000-00003. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8811493

10

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.

Albertini MR, Gan J, Jaeger P, Hank JA, Storer B, Schell K, Rivest T, Surfus J, Reisfeld RA, Schiller JH, Sondel PM. Albertini MR, et al. J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):278-95. doi: 10.1097/00002371-199607000-00004. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8877722

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

96 results

Search Page